Discovered by KalVista, sebetralstat is an investigational novel, orally-administered therapy for the on-demand treatment of HAE. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its …

Sebetralstat is an investigational new drug that is being evaluated for the treatment of hereditary angioedema. [1] It is a plasma kallikrein inhibitor. [2]

May 31, 2024 · Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.

Sebetralstat is an oral plasma kallikrein inhibitor in development for the on-demand treatment of hereditary angioedema attacks in adults and pediatric patients aged 12 years and older.

In KONFIDENT-S, sebetralstat has enabled patients to treat attacks early with a median time from attack onset to treatment of 9 minutes, demonstrated a consistent safety and efficacy profile with KONFIDENT, and included a median time to beginning of …

Abstract: Sebetralstat is a novel, potent, and selective oral plasma kallikrein inhibitor drug candidate in clinical development for the on-demand treatment of hereditary angioedema (HAE).

Sebetralstat, an oral plasma kallikrein (PKa) inhibitor, was evaluated in KONFIDENT,6 a randomized, double-blind, placebo-controlled, phase 3 crossover trial for on-demand treatment of HAE-C1INH. Compared with placebo, sebetralstat provided significantly faster symptom relief, reduction in attack severity, and complete attack resolution.

Dec 1, 2024 · Sebetralstat administered orally at doses of 300 mg or 600 mg for the on-demand treatment of HAE attacks is superior to placebo and resulted in a faster time to symptom relief, reduction in severity of episodes, and increased percentage of attacks, with complete resolution within 24 hours of administration of trial agent.

A phase 2 trial of sebetralstat, a novel oral plasma kallikrein inhibitor for on-demand treatment in hereditary angioedema (HAE), met its primary endpoint (NCT04208412).

Feb 11, 2023 · Sebetralstat (KalVista Pharmaceuticals) is a novel oral plasma kallikrein inhibitor that is in development for the on-demand treatment of hereditary angioedema attacks.